These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2211440)

  • 1. In-vitro sensitivity tests and in-vivo efficacy of cephalosporins against Bacteroides fragilis.
    Brook I
    J Antimicrob Chemother; 1990 Jul; 26(1):158-61. PubMed ID: 2211440
    [No Abstract]   [Full Text] [Related]  

  • 2. In-vitro and in-vivo activities of a novel cephamycin MT-141 against the Bacteroides fragilis group in comparison with six cephem antibiotics.
    Kasai T; Hara T; Tamura A; Kazuno Y; Inouye S; Goto S; Kuwahara S
    J Antimicrob Chemother; 1985 Jun; 15(6):701-14. PubMed ID: 3928575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro and in vivo antimicrobial activities of cefmetazole against Bacteroides fragilis].
    Isono M; Kawashima K; Yamada N; Aoki M; Kobayashi T; Sawa K; Watanabe K; Ueno K
    Jpn J Antibiot; 1982 Jul; 35(7):1667-72. PubMed ID: 6757469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of cephazolin and other cephalosporins against Bacteroides fragilis.
    Leigh DA; Simmons K
    Scott Med J; 1976 Sep; 20(5):228-31. PubMed ID: 1265472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
    Brook I
    Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins.
    Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T
    Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
    Stearne LE; Goessens WH; Mouton JW; Gyssens IC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3605-11. PubMed ID: 17646416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections.
    Ajiki Y; Koga T; Ohya S; Takenouchi T; Yasuda H; Watanabe K; Ueno K
    J Antimicrob Chemother; 1991 Oct; 28(4):537-46. PubMed ID: 1761449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model.
    Alder J; Clement JJ
    J Antimicrob Chemother; 1993 Feb; 31(2):303-11. PubMed ID: 8463174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic activities of nitrothiazole derivatives in experimental infections with Salmonella typhimurium and Bacteroides fragilis.
    Hof H; Eisenbarth B; Denzler A; Zak O; Schweizer E
    J Antimicrob Chemother; 1985 Aug; 16(2):205-10. PubMed ID: 3905749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
    Brook I
    Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
    Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
    Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteroides fragilis septicemia during cefamandole therapy.
    Righter J
    Can Med Assoc J; 1981 Sep; 125(5):422, 424. PubMed ID: 7284925
    [No Abstract]   [Full Text] [Related]  

  • 16. [Appearance of metronidazole resistance in Bacteroides fragilis].
    Chardon H; Ratignier A; Luneau R; Garrigues B
    Nouv Presse Med; 1977 Jun; 6(24):2165. PubMed ID: 905136
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of Bacteroides fragilis group from clinical specimens following antimicrobial therapy.
    Brook I; Frazier EH
    Can J Microbiol; 1992 Mar; 38(3):226-9. PubMed ID: 1393825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice.
    Rossi R; Castellani P; Younes G; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():149-55. PubMed ID: 2732136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative in vitro activity of 4 cephalosporins on Bacteroides fragilis].
    Castillo AM; Fernández-Crehuet M; Ocete MD; Liébana JJ; Cueto A; Maroto MC; Piédrola MG
    Med Clin (Barc); 1986 Apr; 86(15):624-6. PubMed ID: 3724274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.